BRIDGEWATER, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that company management will participate at the 2015 JMP Securities Life Sciences Conference 2015 taking place at The St. Regis New York from June 23 to June 24. Andy Drechsler, chief financial officer of Insmed, will present a corporate overview on Wednesday, June 24 at 11:30 AM ET.
Mr. Drechsler’s presentation will be webcast live and can be accessed by visiting the investor section of the company’s website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.
Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious rare diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung disease and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.